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Serological testing for anti-neural autoantibodies is important in patients presenting with idiopathic cerebellar
ataxia, since these autoantibodies may indicate cancer, determine treatment and predict prognosis. While some of
them target nuclear antigens present in all or most CNS neurons (e.g. anti-Hu, anti-Ri), others more specifically
target antigens present in the cytoplasm or plasma membrane of Purkinje cells (PC). In this series of articles, we
provide a detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic
implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies
(often referred to as ‘Medusa head antibodies’ due their characteristic somatodendritic binding pattern when tested
by immunohistochemistry). To assist immunologists and neurologists in diagnosing these disorders, typical
high-resolution immunohistochemical images of all 12 reactivities are presented, diagnostic pitfalls discussed and
all currently available assays reviewed. Of note, most of these antibodies target antigens involved in the mGluR1/
calcium pathway essential for PC function and survival. Many of the antigens also play a role in spinocerebellar
ataxia. Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol
1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia
(ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating
protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge
on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar
degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic
aspects, and provides a summary and outlook.
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Autoimmune cerebellar ataxia (ACA) is an important
differential diagnosis in patients presenting with signs
and symptoms of cerebellar disease. Alongside multiple
sclerosis and acute disseminated encephalomyelitis,
autoantibody-associated disorders of the central nervous
system (CNS) are the most common cause of ACA.
While ACA is a rare manifestation in some of those dis-
orders, such as aquaporin-4 (AQP4) antibody-associated
neuromyelitis optica (NMO), it is the most frequent or
exclusive presentation in others. To date, around 30 dif-
ferent autoantibodies targeting brain antigens have been
reported in patients with ACA, many of which are of
paraneoplastic origin.
When tested by immunohistochemistry (IHC) using
cerebellum tissue sections, some of these antibodies show
a staining pattern resembling a Gorgon’s head, caused by
binding of immunoglobulin G (IgG) to Purkinje cell (PC)
somata and dendrites, and are therefore often referred to
as ‘Medusa head’ antibodies. Most of these antibodies are
involved in regulation of calcium homoeostasis in PCs.
In part 1 of this series of articles, we focused on anti-
metabotropic glutamate receptor 1 (mGluR1)-, anti-
Homer protein homolog 3 (Homer3)-, anti-Sj/inositol
1,4,5-trisphosphate receptor (ITPR1)- and anti-carbonic
anhydrase-related protein VIII (CARP VIII)-associated
ACA [1]. In the present, second part, we summarise the
current knowledge on anti-protein kinase C gamma
(PKCγ)-, anti-glutamate receptor delta-2 (GluRδ2)-, anti-
Ca/RhoGTPase-activating protein 26 (ARHGAP26)- and
anti-voltage-gated calcium channel (VGCC)-associated
ACA.
Anti-PKCγ
Clinical, paraclinical and epidemiological features
Autoantibodies to PKCγ were first reported in 2006 in a
47-year-old male patient with paraneoplastic cerebellar
degeneration (PCD), cerebrospinal fluid (CSF) pleocytosis
and serum antibodies to PKCγ [2]. The patient’s exact
clinico-neurological status and his brain MRI findings
were not reported. A second patient presented with
vertigo, vomiting, gait and limb ataxia, dysdiadochokinesia
and dysarthria; CSF findings were normal; and MRI was
not reported [3].
Tumour association
Anti-PKCγ autoantibodies were discovered by screening
a series of patients with PCD and non-small-cell lung
cancer for unknown serum reactivities. While the non-
small-cell lung cancer (NSCLC) of the index patient
strongly expressed PKCγ and accordingly immunor-
eacted with the patient’s serum, NSCLC from patients
without PCD did not express PKCγ at either RNA or
protein level, strongly corroborating a paraneoplasticpathogenesis in this case [2, 4]. Neurological symptoms
preceded tumour diagnosis by 2.5 months. In the second
patient, tumour screening revealed a papillary adenocar-
cinoma of hepatobiliary origin infiltrating the liver.Outcome and prognosis
The index patient developed moderately severe dis-
ability. When last examined, he was unable to attend
to his own bodily needs without assistance or to walk
unassisted (Rankin score 4). He later died from can-
cer despite chemotherapy. The second patient was
lost to follow-up after cancer therapy [3].Antigen
PKCγ is a brain neuron-specific member of the classical
protein kinase C (PKC) family. Upon binding of cytosolic
Ca2+ released by ITPR1 to its Ca2+-binding C2 domain, it
is translocated to the plasma membrane, where it gets ac-
tivated by diacylglycerol (DAG) binding to its C1 domain
[5, 6]. PKC modulate the function of other proteins by
phosphorylation of hydroxyl groups of threonine and
serine amino acid residues and are involved in several
signal transduction cascades.
PKCγ, which is expressed exclusively in neurons
within the CNS, is thought to be involved in synaptic
transmission, in particular in modulation of synaptic
plasticity for long-term potentiation (LTP) and long-
term depression (LTD) [5]. While PKC inhibitors
block LTD in cultured rodent PCs, PKC activators
mimic LTD [7, 8]. PKC have been implicated in
desensitising mGluR1 by phosphorylation, which is
thought to play a role in restitution of membrane
potentials after action potential propagation, and acti-
vation of mGluR1 has been shown to generate oscilla-
tory DAG, IP3 and calcium that respond to
oscillations in the activation of PKC [9–12]. PKCγ
was also reported to phosphorylate and block DAG-
activated canonical transient receptor potential chan-
nels (TRPCs) [13, 14], resulting in reduced permeabil-
ity for calcium ions [15]. PKCγ also modulate the
function of GluR4-containing α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors
by directly binding to GluR4 in the cerebellum; phos-
phorylation by PKC seems to target the receptor to
the plasma membrane [16]. The activity of PKCγ, on
the other hand, is indirectly regulated by DAGKη und
DAGLα, which catalyses the hydrolysis of DAG [17].
Calcium and DAG binding recruits PKCγ to the
plasma membrane, where it binds to membrane-linked
receptors for activated C kinases (RACK) [18, 19]. Two
isoforms of human PKCγ produced by alternative splicing
are known.
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PKCγ expression is restricted to the CNS. Within the
CNS, PKCγ is expressed at highest levels in the cerebel-
lum (Fig. 1), followed by hippocampus and cerebral cortex
[5, 20]. Using high-resolution immunogold cytochemistry
of embedded PCs, staining of the plasma membrane of the
dendrites, including the spines, with most intense staining
in the PSD, cell body and, particularly, the initial segment
of the PC axons, was observed [21]. Of note, two pools of
PKCγ were distinguishable, a membrane-associated pool
and a cytoplasmic pool located within 50 nm of the plasma
membrane [21]. In addition, PKCγ was found to be
enriched in the PC axon terminals in the dentate nuclei
[21]. Organelle-related PKCγ was detected only on the
trans-face of the Golgi apparatus.
In the two index patients, avidin–biotin immunoperoxi-
dase IHC on frozen sections of paraformaldehyde-fixed rat
cerebellum was used to detect anti-PKCγ [2, 3]; Sabater
et al. used in addition human tissue [2]. The antibodies in-
tensely labelled PC cytoplasm, dendrites and axons [2]. In
addition, the plasma membrane of neurons in the deep
cerebellar nuclei was outlined in a punctate manner corre-
sponding to densely apposed synaptic terminals of Purkinje
cell axons [2, 3]. By contrast, no reactivity was observed in
non-CNS rat tissues [2]. Höftberger et al. reported binding
of anti-PKCγ also to paraffin-embedded tissue [3]. Figure 2Fig. 1 Expression of PKCγ in the human cerebellum as demonstrated by IHshows staining of snap-frozen and formalin-fixed cere-
bellum tissue by anti-PKCγ as detected by indirect
immunofluorescence.
Antigen-specific assays
Anti-PKCγ has been shown to react with an 80-kilodalton
(kDa) band in immunoblots of rat cerebellum [2, 3]. A
commercial primate cerebellum blot was shown to con-
tain PKCγ using a polyclonal antibody but has not been
evaluated with patient serum [22]. So far, no PKCγ-
specific cell-based assay (CBA) is available.
CSF testing
No data on PKCγ levels in the CSF have been reported
so far.
Association with other autoantibodies
Sabater et al. did not find PKCγ immunoreactivity in
the serum of 105 patients with anti-Hu (n = 50), anti-
Yo (n = 30) or anti-CV2 (n = 25) antibodies [2].
Pathogenetic relevance
The fact that PKCγ is an intracellular antigen located on
the cytoplasmic side of the plasma membrane argues a
priori against a role of antibody-dependent cell- or
complement-mediated cytotoxicity. However, uptake ofC (modified image from the Human Protein Atlas image database [20])
Fig. 2 Binding of anti-PKCγ from a patient with ACA to a monkey cerebellum tissue section. The patient antibody was detected by use of a goat
anti-human IgG secondary antibody labelled with Alexa Fluor® 488 (green)
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dependent studies [23–32]. Given the important role of
PKCγ in regulating important signalling pathways, a
functional impact of anti-PKCγ thus cannot be com-
pletely ruled out.
Molecular genetics
Numerous mutations in the PKCγ gene have been found
in patients with SCA14, which is characterised by slowly
progressive, adult-onset cerebellar gait and limb ataxia,
dysarthria and eye movement disturbances [33–42].Some mutations were accompanied by moderate intel-
lectual disability [42]. While mutations affecting the
regulatory domain have been reported to be associated
with a relatively pure form of SCA14 and onset in the
third or fourth decade of life, mutations in the catalytic
domain affect both children and adults and are associ-
ated with cognitive impairment in some cases [40, 43].
Selected PKCγ mutants show an increase instead of loss in
kinase activity. This leads to aprataxin (APTX), a deoxy-
ribonucleic acid (DNA) repair protein, being prevented
from entering the nucleus due to phosphorylation and, in
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damage and cell death [41]; mutations in the APTX gene
underlie early-onset ataxia with oculomotor apraxia and
hypoalbuminaemia [44]. Chen et al. found a reduction in
immunoreactivity for ataxin-1 (ATXN1) in PC of patients
with SCA14 due to PKCγ mutation [33]; on the other
hand, loss of PKCγ may also contribute to PC pathology in
SCA1, which is primarily caused by the expression of mu-
tant ATXN1 [45]. PKCγ-deficient mice exhibit, alongside
other symptoms, impaired motor coordination, probably
caused by persistent multiple innervations of climbing
fibres (CFs) on PC [5, 46]. Multiple innervations have also
been observed in PKCγ mutant mice [47].Anti-GluRδ2
Clinical, paraclinical and epidemiological features
Antibodies to GluRδ2 (immunoglobulin G [IgG] and M
[IgM]) were first reported in 2004 in a 20-month-old child
[48] and again in 2010 in two boys (18 months and
13 years of age, respectively) with cerebellar ataxia, one of
whom was positive for GluRδ2-IgM instead of IgG [49,
50]. Clinical findings included dysmetria, dysdiadochokin-
esis, tremor, muscular hypotonia and gait ataxia.
Four additional patients, a 13-year-old girl with severe
truncal ataxia [51] and three women aged 36, 45 and
59 years with ‘non-herpetic acute limbic encephalitis’
[52–55] were in addition positive for antibodies to the
glutamate receptors epsilon2 (GluRε2), i.e. the N-methyl-
D-aspartate receptor subtype 2B (NMDAR2B or NR2B),
which have been described in patients with acute limbic
encephalitis [52, 56–59]. In a young boy who had acute
encephalitis with refractory, repetitive partial seizures,
anti-GluRδ2 antibodies were reportedly present in addition
to antibodies to GluRε2/NR2B and antibodies to the
glutamate receptor zeta2 (GluRζ1) [60], i.e. the NMDA
receptor subtype NMDAR1A or NR1A, the main target
in anti-NMDAR receptor encephalitis [61].
MRI was normal in the index patient [48]. In the sec-
ond patient, MRI revealed swelling (and later atrophy)
of the left cerebellar hemisphere and obstructive hydro-
cephalus [49]. In the third patient, no cerebellar ataxia
but meningeal enhancement was detected [50]; menin-
geal signs had been present also in patient 2. In a patient
with anti-GluRδ2 and anti-GluRε2 antibodies, MRI
findings normalised after plasma exchange (PEX) treat-
ment [54].
In patient 2, lymphocytic CSF pleocytosis (404 cells/μl)
was noted with negative oligoclonal bands (OCB). Lumbar
puncture was normal in patient 3 at onset and demon-
strated predominantly mononuclear pleocytosis but nega-
tive OCB later in the disease course. OCB were also
lacking in the patient with anti-GluRδ2, anti-GluRε2 and
anti-GluRζ1.Tumour association
No tumours have been reported so far in patients with
anti-GluRδ2-associated cerebellar ataxia. Of note, how-
ever, all cases were preceded or accompanied by either
infection or vaccination.
Outcome and prognosis
In the index patient, intravenous immunoglobulins (IVIG)
and intravenous methylprednisolone (IVMP) failed to
ameliorate the symptoms; symptoms were still present
2 years later and were then accompanied by mental re-
tardation [48]. The second patient recovered without any
sequelae within 3 weeks following treatment with IVMP
[49]. In the third patient, ataxia spontaneously and grad-
ually improved, but worsened again following vaccination
against mumps and varicella zoster. Interestingly, CSF
neuron-specific enolase (NSE) levels correlated with the
cerebellar symptoms in the index patient.
In those cases positive for anti-GluRδ2 and anti-
GluRε2 and/or GluRζ1, cerebellar symptoms were per-
sistent in the child (treatment status not reported) [51],
while they completely disappeared in an adult patient
after seven PEX treatments and around 2 months after
onset [54]. In the remaining cases, limbic signs were pre-
dominant and either persisted [52] or were fatal within
2 weeks [53].
Antigen
The protein termed glutamate receptor delta-2 (GluRδ2,
also known as GluD2), encoded by the GRID2 gene, is
nominally a member of the ionotropic glutamate receptor
family of excitatory neurotransmitter receptors. However,
as it is the case with GluRδ1, this classification is mainly
based on sequence homology. It is still controversial
whether GluRδ2 can in fact form functional ligand-gated
ion channels in vivo [62]. While it does not recognise
L-glutamate or glutamate analogues, the ligand-binding
core of GluRδ2 binds neutral amino acids such as D-
serine and glycine [63]. No functional incorporation of
GluRδ2 into native ionotropic GluRs could be demon-
strated [64], and obtaining ion channel function required
ligand-binding domain transplantation from other glutam-
ate receptors [65]. Thus, it has been proposed that the re-
ceptor might have other (e.g. modulatory) functions rather
than serving as an ion channel [64, 66, 67]. Alternatively,
GluRδ2 may be a ‘switchable’ receptor, the ionotropic
functions of which may be controlled by yet uncharac-
terised proteins [65].
GluRδ2 is selectively expressed in PCs [68–70] and
has been demonstrated to have an important role in
long-term synaptic plasticity in the cerebellum and thus
in motor learning [66, 67, 71, 72]. Recently, it was shown
that GluRδ2 associates in PCs with mGluR1 and PKCγ,
both of which have also been identified as target
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mGluR1/DAG- and PKCγ-regulated TRPC3, which is
needed for mGluR1-dependent slow EPSCs [73]. Ac-
cordingly, mutations in GluRδ2 were associated with ab-
normal mGluR1-dependent synaptic transmission at
parallel fibre (PF)/PC synapses, partly by increased sur-
face expression of mGluR1 and TRPC3 and mGluR1-
evoked inward currents [73]. It has been suggested that
GluRδ2 interacts with mGluR1alpha in the dendritic PC
spines through the PDZ domains of two members of the
Shank family of scaffold proteins, namely Shank1 and
Shank2, through which it is associated also with ITPR1,
Homer proteins and AMPA receptors [74]. Via β-III
spectrin, mutations in which underlie SCA5, GluRδ2 is
anchored to the plasma membrane [75]. Upon intracel-
lular calcium release that binding is disrupted and
GluRδ2 gets declustered at the postsynaptic sites [76].
Moreover, GluRδ2 has been suggested to be essential
for PF/PC synapse formation in the cerebellum involving
trans-synaptic interaction of the N-terminal domain of
the receptor via cerebellin-1 precursor protein (Cbln1,
precerebellin) with presynaptic neurexins [77, 78].
Immunohistochemistry
GluRδ2 is thought to be selectively expressed in the
cerebellum [68, 69]. It is mainly localised in the PCFig. 3 Expression of GluRδ2 in the human cerebellum as demonstrated by IHdendritic spines at PF/PC synapses [68, 79] (Fig. 3). As
anti-GluRδ2 was originally detected by enzyme-linked
immunosorbent assays (ELISA) only, no images demon-
strating the IHC binding pattern of anti-GluRδ2-
positive sera have previously been published. Figure 4
shows for the first time the binding of a GluRδ2-
positive serum sample to cerebellum tissue.Antigen-specific assays
Western blot of primate cerebellum extract has been
reported to contain a 62- to 80-kDa band correspond-
ing to GluRδ2, as indicated by binding of a commer-
cial, polyclonal GluRδ2-specific antibody, and might
thus be capable of detecting anti-GluRδ2 [22]. An
ELISA was used in the studies by Kinno et al. and
Shimokaze et al., but no details were reported [49, 54].
Moreover, a CBA employing HEK293 transfected with
human GluRδ2 (Euroimmun, Luebeck, Germany) is
available at the authors’ institution for use in scientific
studies.CSF testing
GluRδ2 antibodies were detected both in serum and in
the CSF in two patients (1 × IgG, 1 × IgG and IgM), only
in the serum in one, and only in the CSF in two cases.C (modified image from the Human Protein Atlas image database [20])
Fig. 4 Binding of anti-GluRδ2 from a patient with ACA to a monkey cerebellum tissue section. The patient antibody was detected by use of a
goat anti-human IgG secondary antibody labelled with Alexa Fluor® 488 (green)
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Anti-GluRδ2 have been reported in association with anti-
GluRε2 (NR2B) [51–54] and GluRζ1 (NR1) antibodies
[60]. The 36-year-old woman with anti-GluRδ2 and anti-
GluRε2 was also tested for antibodies to the NR1/NR2B
(GluRζ1/GluRε2) heterodimer, but was negative.
Pathogenetic relevance
A potential pathogenic role of anti-GluRδ2 in ACA is
conceivable given that GluRδ2 is predominantly expressed
in PCs, GluRδ2 is present on the cell surface, anti-GluRδ2was detected in the CSF in some cases, GluRδ2
mutations are associated with ataxia (see below), and
PEX had a therapeutic effect in individual patients.
Of note, injection of polyclonal antibodies specific for
the putative ligand-binding region of GluRδ2 gener-
ated by immunisation of rabbits with a synthetic
peptide into the supracerebellar subarachnoid space
was shown to cause AMPA receptor endocytosis,
attenuate synaptic transmission and abrogate long-
term depression in PC cultures and transient ataxia
in mice [80].
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In 2013, two families were identified in which a homozy-
gous deletion of GRID2 exon 4 and compound heterozy-
gous deletions involving GRID2 exon 2, respectively,
were associated with cerebellar ataxia, tonic upgaze and
delayed cognitive and speech development. Recently, a
de novo 276-kb deletion encompassing the first exon of
the GRID2 gene encoding GluRδ2 was reported in a sin-
gle patient, associated with cerebellar ataxia but also
spastic paraplegia, frontotemporal dementia and lower
motor neuron disease [81]. Finally, mutations in beta-3
spectrin underlying SCA5 were shown to affect the sub-
cellular localisation of GluRδ2 [75]. While the receptor
was enriched in the synaptosomal fractions in controls,
it was not enriched in SCA5 autopsy tissue.
Additional evidence for an essential role in motor co-
ordination comes from mutant mice experiments. Mice
with a disrupted GluRδ2 locus show locomotor ataxia,
disturbed PC synapse formation and impaired cerebellar
LTD [82]. A recent study found that in GluRδ2 knock-
out mice, surplus CFs make ectopic innervations onto
distal dendrites of PCs and a higher and more wide-
spread synchrony of calcium transients in neighbouring
PCs occurs. Moreover, transverse CF collaterals and CF
signals transgress PC microzone borders, form ectopic
synapses onto neighbouring PC dendrites and exhibit
clustered firing not present in wild-type mouse [83]. Fi-
nally, mutations in the Grid2 gene have been found to
be the cause of ataxia in ‘lurcher’ mice, which are char-
acterised by apoptosis of PCs during postnatal develop-
ment, and ‘hotfoot’ mice [84, 85].
Anti-Ca/ARHGAP26
Clinical, paraclinical and epidemiological features
Antibodies to ARHGAP26 (also termed anti-Ca) were first
described in 2010 [22]. So far, four patients with Ca/ARH-
GAP26 antibodies have been published [22, 86, 87]. Age at
diagnosis was 24, 33, 38 and 68 years. Two patients were fe-
male and two male. Recently, two additional cases have
been identified by the authors (unpublished data, S.J.).
All of the patients reported thus far suffered from cere-
bellar ataxia, which developed subacutely within a few
days in two out of the three patients with available data.
The index patient presented with limb and severe gait
ataxia, horizontal nystagmus, oscillopsia and dysarthria.
Symptoms had developed within 5 days and had been
preceded by a common cold 2 weeks before onset. Patient
2 developed a multidirectional gaze-evoked nystagmus,
cerebellar dysarthria, atactic gait, severe difficulties in
standing with her feet and her eyes open, and severely im-
paired tandem walk; 4 months before onset, she had been
admitted to hospital with a 2-month history of dizziness,
but MRI revealed no abnormality at that time. Patient 3
had a 9-month history of cerebellar ataxia and dysarthria,but no detailed clinical data were available. Patient 4 also
presented with cerebellar gait ataxia, which progressed
within a few days to panataxia with inability to walk un-
assisted. In addition, severe dysarthria, gaze-evoked nys-
tagmus and disrupted vestibulo-ocular reflex cancellation
with oscillopsia were noted. The patient reported slight
weight loss, headaches and sweating at night, but no pre-
ceding infection or vaccination [87].
Some evidence suggests that anti-Ca/ARHGAP26 auto-
immunity might possibly affect also areas outside the
CNS. Interestingly, the index patient developed an in-
creased startle response and a brisk head retraction reflex
2 months after onset, suggestive of symptomatic hyperek-
plexia, a condition often caused by brain stem lesions.
Moreover, severe depression, restlessness and anxiety were
noted, compatible with possible involvement of the limbic
system.
On the other hand, occasional cases of secondary
hyperekplexia due to cerebellar pathology have been re-
ported [88], and a combination of steroid-induced and
reactive depression would sufficiently explain the index
patient’s psychiatric symptoms [22].
Symptoms in patient 2 and 3 included nausea and
vomiting. In patient 4, cognitive decline, a flattened affect,
working memory deficits, compromised verbal learning
and recall, attention deficits, slowed information process-
ing, interference difficulty and reduced spatial recognition
were present in addition to a pancerebellar syndrome [87].
While some of the neuropsychological deficits could be
explained by the so-called cerebellar cognitive-affective
syndrome, which is characterised by impairments in vis-
ual–spatial abilities and affective disturbances such as
emotional blunting and depression [89], the verbal learn-
ing and recall deficits may indicate limbic system involve-
ment [87]. ARHGAP26 is indeed detectable in a subset of
neurons in the hippocampus.
Lumbar puncture revealed CSF pleocytosis (5, 35 and
44 cells/μl; lymphocytic in two, with a few plasma cells
in one; not specified in the remaining cases) and CSF-
restricted OCB in all three patients tested. An increased
IgG and IgM CSF/serum ratio was reported in one pa-
tient and an increased CSF/serum albumin ratio, indicat-
ing blood–CSF barrier dysfunction, in two (no data in
the remainder).
Brain MRI was normal at onset in the index patient,
but disclosed progressive cerebellar atrophy at month 4
and month 17 with marked widening of the cerebellar
sulci and the fourth ventricle. An FDG-PET examination
at month 6 revealed relative hypometabolism of the right
cerebellar hemisphere. In patient 2, cerebral MRI was
also unremarkable at onset but revealed cortical atrophy
in the cerebellar hemispheres and the inferior vermis
with enlargement of the cerebellar sulci, the fourth ven-
tricle and the inferior cerebellar cistern when repeated
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or pons was noted. Patient 3 developed cerebellar atro-
phy, but no detailed data were reported. Patient 4 again
had a normal MRI at onset but mild cerebellar atrophy
was notable by month 4; repeat MRI 4 years after onset
showed severe pancerebellar atrophy.
Tumour association
Patient 2 was diagnosed with a (reportedly non-differenti-
ated) ovarian carcinoma. Positive serum tumour markers
in that patient included cancer antigen (CA)125, CA15-3
and NSE; in addition, an elevated erythrocyte sedimenta-
tion rate and increased lactate dehydrogenase blood levels
were noted. At the time of first tumour diagnosis, lymph
node metastasis was present. Eight months after chemo-
therapy, new metastases were found. Mild to moderate
ARHGAP26 has been detected in numerous tumour
types, including ovarian cancer, by IHC [20]. In patient 3,
who is lost to follow-up, marked weight loss and fever was
noted at the time of diagnosis. The remaining two patients
were without malignancy at 4 and 6 years, respectively,
after disease onset. Of note, in two out of the three cases
with available data, onset of disease was preceded by
infection.
Outcome and prognosis
While a mild to moderate effect of steroids, rituximab
and/or IVIG was noted at early stages, no such effect was
observed later in the disease course. It is conceivable that
the later stages reflect complete loss of Purkinje cells. In
two cases with available data, rehabilitation resulted in
some improvement.
In the index case, IVMP treatment with oral tapering was
initially followed by marked neurological improvement.
However, when steroids were reduced to 12.5 mg MP per
day a significant worsening of symptoms occurred. While
a further course of IVMP as well as treatment with IVIG
was without effect, the cerebellar syndrome stabilised and
improved following PEX and immunoadsorption. The ex-
aggerated startle response responded to lorazepam. At last
evaluation, 16 months after onset, the patient presented
with cerebellar signs and hyperekplexia without significant
further progression [22]. In patient 2, treatment with car-
boplatin and docetaxel for ovarian carcinoma and with ri-
tuximab and IVIG resulted in partial amelioration of the
neurological symptoms. A relapse occurred, however,
requiring double adnexectomy, hysterectomy and second-
line chemotherapy with carboplatin and cyclophospha-
mide. Despite that treatment, symptoms continued to
advance slowly and increasing gait instability, nausea and
vomiting were present at last follow-up [22]. In patient 4,
treatment with IVMP with oral tapering was followed
by some temporary improvement; however, the patient
remained unable to walk independently. Over thefollowing 6 months, his cerebellar symptoms continued
to deteriorate slowly, leaving him wheelchair-bound.
While a further IVMP course in month 8 remained
without effect, intensive rehabilitation was paralleled by
clinical stabilisation at 12 months after onset and slight
improvement at 24 months; after 3 years, the patient
was able to walk with a stroller. However, at 4 years
after onset his gait ataxia was gradually worsening. His
affective disorder did not improve [87].
Antigen
ARHGAP26 (also termed oligophrenin-like protein) is a
GTPase-activating protein originally identified in avian
cells, where it binds in an SH3 domain-dependent manner
to the C-terminal domain of focal adhesion kinase (FAK),
a tyrosine kinase believed to be an essential component of
the integrin signalling transduction pathway regulating,
inter alia, the organisation of the actin cytoskeleton upon
cell–cell/cell–matrix contacts; ARHGAP26 is therefore
also called GTPase regulator associated with focal adhe-
sion kinase 1 (GRAF1) [90]. It has been shown to regulate
negatively the small GTP-binding Ras homolog gene fam-
ily, member A (RhoA) by stimulating its GTPase activity
[90], which is involved in actin organisation, cell cycle
maintenance, cellular development and transcriptional
control. ARHGAP26 is a multidomain protein containing
membrane-binding and -modulating Bin–amphiphysin–
Rvs (BAR) and PH domains, a Rho GTPase-activating
protein (GAP) domain and a dynamin- and FAK/PAK-
binding SH3 domain and functions at the interface be-
tween membrane sculpting, small G-protein signalling
and endocytosis [91]. It has been proposed to regulate the
clathrin-independent, so-called CLIC/GEEC endocytotic
pathway [92], which, by coordinating membrane remodel-
ling into tubulovesicular carriers, mediates lipid-anchored
receptor endocytosis [93] and which is able to internalise
GPI-linked proteins, bacterial exotoxins and large
amounts of extracellular fluid [91, 94]. These carriers are
associated with the activity of cell division cycle 42
(Cdc42), a small GTP-binding protein activated by ARH-
GAP26 [90]. A model proposed by Doherty and Lund-
mark involves clustering of receptors in nanodomains of
the plasma membrane that are recognised by Cdc42
(and Arf1) inside the cell; subsequently, GRAF1 is re-
cruited to the membrane bud, resulting in the formation
of a membrane tubule eventually released from the plasma
membrane via a scission reaction [91].
The exact cell biological functions of this highly preva-
lent endocytic pathway are partly unclear. Among other
functions, it has been proposed that ARHGAP26 re-
models membrane microdomains at adhesion sites into
endocytic carriers, facilitating membrane turnover during
cell morphological changes [93], thereby giving it a role in
cell spreading and migration. The biogenesis of tubular
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volved, and their subsequent vesiculation after cargo sort-
ing has occurred, has a role in receptor and lipid recycling
to the plasma membrane [95]. In myoblasts, ARHGAP26
has been implicated in cell fusion during muscle matur-
ation by actin remodelling and BAR-dependent membrane
binding or sculpting [96].
On a subcellular level, ARHGAP26 localises to the
membrane of highly prevalent, dynamic and pleo-
morphic tubular and punctate endocytic carriers via its
N-terminal BAR and PH domains. ARHGAP26 has been
shown to have effects on cell shape and actin localisation
also in neuronal cells, as indicated by enhanced SPP-
induced and GAP domain-dependent neurite retraction
in nerve growth factor-differentiated PC12 cells overex-
pressing the protein [97].
Interestingly, ARHGAP26 interacts strongly with the
membrane scission protein dynamin, another protein
with GTPase activity [92]; accordingly, dynamin was
found to co-precipitate with ARHGAP26 upon incuba-
tion with anti-Ca/ARHGAP26 [22]. Dynamin is involved
also in the classical, clathrin-mediated endocytotic
pathway, where it is recruited to sites of endocytosis in
γ-aminobutyric acid (GABA)-ergic neurons by amphi-
physin, a well-established paraneoplastic autoantigen
associated with stiff-person syndrome and a broadFig. 5 Expression of ARHGAP26 in the human cerebellum as demonstrated byspectrum of other neurological syndromes including
progressive cerebellar degeneration [98–100]. The as-
sociation of ARHGAP26 with dynamin and thus, po-
tentially, also with the clathrin-mediated endocytotic
pathway is of particular interest, since it would link
ARHGAP26 to mGluR1 turnover (and thus to LTD).
Agonist application has been shown to cause rapid in-
ternalisation of mGluR1 through a dynamin-dependent
process [101, 102] triggered by a signalling cascade
involving β-arrestin-1 [11, 103], and internalised
mGluR1a has been found colocalised with clathrin in
endocytic vesicles [11].
Interestingly, PKN-beta, a fatty acid-activated serine/
threonine protein kinase, has been shown to interact
both with ARHGAP26 and with paraneoplastic cerebel-
lar degeneration 17 (PCD17), or CDR2, the target anti-
gen precipitated by anti-Yo-positive sera from patients
with ACA (see the section entitled Anti-Yo/CDR2/
CDR62 (PCA1)’ in Part 3 of this article series) [104,
105]. Figure 5 shows the expression pattern of ARH-
GAP26 in the human cerebellum.
Immunohistochemistry
When tested on snap-frozen cerebellum sections, anti-
Ca/ARHGAP26 antibodies bind to the somata, dendrites
(including spines) and axons of PCs (Fig. 6). Usually, theIHC (modified image from the Human Protein Atlas image database [20])
Fig. 6 Binding of IgG from a patient with ARHGAP26-Ab-positive ACA to a mouse cerebellum tissue section. An Alexa Fluor® 488-labelled goat
anti-human IgG antibody (green fluorescence) was used to visualise bound patient IgG. ML=molecular layer, PCL= Purkinje cell layer, WM=white
matter, GL = granular layer, P = pia mater. Image taken from Jarius et al. [22]
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is less pronounced than that of the dendritic tree. Stellar
cells, basket cells, Golgi cells and the granular cells as
well as their processes (including the parallel fibres) are
all spared, as are the glial cells of the cerebellum and
their processes. On intestinal tissue sections, binding to
the plexus myentericus has been noted with high-titre
samples. Incubation of hippocampal sections with anti-
Ca/ARHGAP26-positive sera has resulted in staining of
single neurons; however, as not all sera seem to bind tohippocampal neurons, the significance of this finding is
unknown.
In accordance with their target antigen’s intracellular
location, anti-Ca/ARHGAP26 did not bind to non-
permeabilised cultured, live PCs but only to cultured
PCs fixed and treated with CHAPS or Triton X [22].
However, the antibodies can be readily detected by IHC
using non-fixed/non-permeabilised tissue if very thin
sections (e.g. 5–7 μm) are used, since such sections
mostly contain dissected neurons.
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A dot–blot assay, a preadsorption IHC assay and a
HEK293-CBA (Euroimmun), all of which employ recom-
binant human ARHGAP26, are available at the authors’
institutions for use in scientific studies. When tested in a
commercial cerebellum Western blot assay, anti-Ca/
ARHGAP26-positive serum and CSF samples bound to
an 80- to 97-kDa band [22].
CSF testing
Anti-Ca/ARHGAP26 antibodies have been detected in
the CSF of the only two patients examined [22]. In both
cases, intrathecal synthesis as indicated by an elevated
ARHGAP26-specific antibody index was noted [22].
Based on these limited data, testing of serum samples,
which yielded higher titres than CSF in those two cases,
may be sufficient. However, testing of the CSF may be a
promising option if serum testing is hampered by non-
specific background issues and/or the presence of
additional autoantibodies.
Association with other autoantibodies
Additional systemic autoantibodies (anti-nuclear anti-
bodies [ANA] reacting with coilin) and anti-thyroidal
antibodies (anti-thyroperoxidase, anti-TSH receptor)
were present in two cases with available data, suggesting
a more general autoimmune predisposition. However, no
additional anti-neuronal antibodies were found.
Pathogenetic relevance
A potential pathogenic role is suggested by the fact that
the antibody is usually present at high titres, is produced
intrathecally, belongs to the IgG1 subgroup and was as-
sociated with PCD in all cases reported thus far. How-
ever, ARHGAP26 is believed to be an intracellular
antigen, rendering it possible that the actual damage is
caused by T cells rather than by the antibody itself. Pas-
sive transfer experiments are currently under way.
Of note, anti-coilin ANA were present in the index pa-
tient. P80 coilin has been reported to interact with and
possibly alter the function of ataxin-1, a protein involved
in SCA1. However, anti-coilin ANA are not normally as-
sociated with ACA, rendering it a priori unlikely that
these antibodies contributed to that patient’s neuro-
logical condition. Moreover, anti-coilin ANA were ab-
sent in all other published patients and in all subsequent
cases, as yet unpublished, diagnosed at our laboratory.
Molecular genetics
ARHGAP26 has not been implicated in SCA to date.
However, somatic mutations of ARHGAP26 have been
identified as a rare cause of juvenile myelomonocytic
leukaemia, one of the most common paediatric myelo-
dysplastic syndromes [106]. The ARHGAP26 gene ishighly homologous to BCR, which is also involved in a
leukaemia-associated translocation [90]. Recently, de-
creased expression of ARHGAP26 has been implicated
in the pathogenesis of X-linked alpha-thalassaemia
mental retardation syndrome [107]. GRAF1 knockout
mice developed normally, were fertile and were of
similar weight as wild-type animals; haematoxylin and
eosin-stained cerebellum and hippocampus sections
showed no gross anatomical abnormalities, though de-
tailed neurological or electrophysiological examinations
were not performed [108].Anti-VGCC
Clinical, paraclinical and epidemiological features
Anti-VGCC autoantibodies have been reported both in pa-
tients with PCD and in patients with non-paraneoplastic
cerebellar ataxia. In addition, they exist both in tumour-
associated and in non-paraneoplastic Lambert–Eaton my-
asthenic syndrome (LEMS).
Graus et al. reported 16 anti-VGCC-positive male pa-
tients with PCD and no CNS symptoms beyond cerebel-
lar ataxia [109]. No detailed data on the patients’
cerebellar symptoms were provided. Nine of the 16 had
no clinical evidence of LEMS at the time of anti-VGCC
testing. No information on MRI and LP results was pro-
vided [109].
Bürk et al. found anti-P/Q-type VGCC antibodies in four
female and four male patients with non-paraneoplastic
cerebellar degeneration. Additional symptoms besides
ataxia, dysarthria and cerebellar oculomotor deficits in-
cluded cognitive symptoms, spasticity, impaired proprio-
ception, double vision, dysphagia, autonomic dysfunction
and basal ganglia symptoms [110]. Four patients had previ-
ously been diagnosed with idiopathic multiple system atro-
phy of the cerebellar type and four with idiopathic late-
onset ataxia. MRI showed cerebellar atrophy in six out of
eight and olivopontocerebellar atrophy in the remainder.
CSF results were not reported.Tumour association
First reports on the association of lung cancer, cerebellar
degeneration and myasthenic symptoms date back to the
1970s [111]. A role of antibodies to VGCC in patients
with PCD was first suggested by Clouston et al., who re-
ported three PCD patients with SCLC, small-cell prostate
cancer or non-Hodgkin lymphoma, respectively, two of
whom had in addition LEMS [112]. Shortly after, Lennon
et al. reported both P/Q- and N-type VGCC antibodies in
an independent cohort [113]; however, no detailed data on
the frequency among the various underlying tumours
were provided, and almost all of the PCD patients
included (n = 34) had additional anti-neuronal antibodies.
In a third study, which comprised only patients with
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VGCC autoantibodies were detected in 12/50 cases (24 %)
using a 125I-ω-conotoxin MVIIC-based assay, including all
patients with signs or symptoms of LEMS but also five
PCD patients without LEMS [114]. By contrast, only 1 of
49 control patients with SCLC but no paraneoplastic CNS
syndrome had P/Q-type VGCC antibodies. Similarly, anti-
bodies to N-type VGCC were detected in the same study
using a 125I-ω-conotoxin GVIA-based radioimmunopreci-
pitation assay (RIA) in 9/50 samples from SCLC-PCD pa-
tients, six of whom (66 %) had no LEMS at the time of
testing. Voltz et al. [115] used a commercial RIA based on
125I-ω-conotoxin MVIIC to detect anti-VGCC in eight out
of 66 patients with SCLC and anti-Hu syndrome. Of these
eight patients, two had PCD without LEMS and two PCD
with LEMS. Of note, none of 27 patients with PCD and
tumours other than SCLC was positive for P/Q-type
VGCC antibodies. By contrast, P/Q VGCC antibodies
were absent in a smaller series of anti-Yo-positive patients
with gynaecological tumours [116]. Graus et al. examined
PCD patients with lung cancer with or without anti-Hu
antibodies (23 %) but with no symptoms beyond the
cerebellum for anti-P/Q-type VGCC, again using a 125I-
ω-conotoxin MVIIC assay, and detected raised levels in
16 (41 %) of 39 patients with positive PCD, 9 of whom
did not have clinical or subclinical LEMS (56 %) and 14
of whom were negative for anti-Hu [109]. The median
time between onset of PCD and tumour diagnosis was
3 months. The most frequent lung tumour diagnosis
was SCLC; only two patients had NSCLC. Except for
the prevalence of LEMS, no relevant differences were
observed between PCD patients with and without
VGCC antibodies. The authors concluded that anti-P/
Q-type VGCC could be a more sensitive marker for
PCD than anti-Hu and in general a useful marker for
lung cancer-associated PCD.
However, anti-VGCC autoantibodies are not always as-
sociated with cancer in patients with cerebellar ataxia.
Clouston et al., in their original series on anti-VGCC in
ataxia patients, reported two non-paraneoplastic cases
[112], and Bürk et al. found P/Q-type VGCC-specific
antibodies in 8/67 (12 %) of patients with non-
paraneoplastic chronic cerebellar degeneration; by con-
trast, sera from 117 control patients were negative in the
latter study [110].
Outcome and prognosis
Outcome and prognosis may depend on tumour diagno-
sis. Graus et al. reported 16 patients with SCLC and
anti-VGCC-PCD, 8 of whom already had a Rankin score
of >3 at first presentation. Nine received tumour treat-
ment and immunotherapy, four only immunotherapy,
and three no treatment. One patient improved, five
stabilised at a low Rankin score (≤3), and five worsenedor stabilised at a high Rankin score (no data for the re-
mainder). Median survival time was 12 months. Interest-
ingly, in the three patients with both PCD (anti-Hu
status not reported) and LEMS, only LEMS improved
following immunotherapy.
A patient with ataxia and anti-VGCC but no additional
antibodies reported by McKasson et al. improved under
treatment with IVIG, prednisone and mycophenolate
mofetil but deteriorated after IVIG was halted because of
aseptic meningitis [117]. After developing LEMS
11 months later, the patient declined further treatment
and elected hospice care.
Anti-neuronal antibodies are thought to improve
survival from SCLC [118]. However, in SCLC patients
without neurological symptoms, no effect of anti-
VGCC on extent of disease or survival was found in
a study comparing 10 anti-VGCC-positive with 143
anti-VGCC-negative patients [119].
Two patients with anti-VGCC autoantibodies but
non-paraneoplastic PCD were still alive 10 and 2 years
after onset [110]. Rigamonti et al. reported a patient
with non-paraneoplastic PCD and subclinical LEMS
with high serum and CSF VGCC titres in whom IVIG
treatment led to clinical improvement and reduction
of serum antibody titre over a 13-month follow-up
period [120].
Antigen
Calcium channels are the main molecular link between
cellular membrane potential changes and intracellular Ca2
+ signalling and can be divided into ligand-gated and
voltage-gated channels. Upon activation, they allow Ca2+
from the extracellular space or from intracellular calcium
stores to enter the cytosol. VGCCs, which are membrane
proteins, are further subclassified according to subunit
composition, voltage dependence and single-channel con-
ductance kinetics. P/Q-type VGCCs are dihydropyri-
dine-insensitive high-voltage threshold-activated (i.e.
they require strong membrane potential depolarising
stimuli for activation) cation channels mediating so-
called P- and Q-type Ca2+ currents [121] and were first
identified in PCs. The channels are made up of the princi-
pal pore- and gating apparatus-forming as well as plasma
membrane voltage-sensing subunit termed alpha-1A
(Cav2.1), which is encoded by the CACNA1A gene, and
the auxiliary channel-trafficking and activity-regulating
subunits beta, alpha-2/delta (disulphide-linked), and, in
some tissues, gamma [122, 123]. They are blocked by
spider and marine snail peptide toxins, in particular by ω-
agatoxin IVA and ω-agatoxin IVB from funnel web spider
venom which bind with high specificity and affinity [124].
P/Q-type VGCCs autoantibodies play an important
role in glutamatergic neurotransmission by being in-
volved in spatiotemporal Ca2+ regulation. They are
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mitter and hormone vesicle release at central and per-
ipheral synaptic terminals, though many other functions
have been described [125–130].
Of note, Cav2.1 and mGluR1a have been shown to be
co-localised at the PC dendritic plasma membrane and to
interact directly via their C-terminal intracellular domains,
forming a heteromeric protein complex [131–133].
MGluR1 is thought to inhibit Cav2.1-mediated Ca
2+
currents both in a ligand-independent manner mediated
by physical coupling to Cav2.1 and in a ligand-
dependent manner mediated by Gi/Go coupling [131,
134, 135]. By contrast, simultaneous stimulation of
mGluR1 and Cav2.1 induces large Ca
2+ increases [131].
Immunohistochemistry
So far, no images showing binding of IgG from anti-
VGCC-positive patients to cerebellum tissue sections
have been published. However, by means of polyclonal
antibodies generated from isolated P-type channels, Hil-
man et al. could demonstrate that P-type VGCCs are
present on the plasma membrane of PC somata and PC
main stems and, at much higher levels, on that of the PC
dendrites, spiny branchlets and spines [136]. Electron mi-
croscopy demonstrated expression also in the PC ER.
Figure 7 shows staining of PC somata and dendrites by a
polyclonal antibody to Cav2.1.
Outside the cerebellum, P-type VGCC autoantibodies
are abundantly expressed throughout the CNS [136–138]:
Strong expression was found in the periglomerular cells of
the olfactory bulb, scattered neurons in the deep layer of
the entorhinal and pyriform cortices, neurons in the brain-
stem, habenula, nucleus of the trapezoid body and inferior
olive and along the floor of the fourth ventricle [136].
Medium-intensity reactions were observed in layer H
pyramidal cells of the frontal cortex, the CA1 cells of the
hippocampus, the lateral nucleus of the substantia nigra,
lateral reticular nucleus and spinal fifth nucleus. Light la-
belling was seen in the neocortex and striatum [136].
Indirati et al. described a somatodendritic gradient of
P/Q-type channels, with the density increasing 2.5-fold
from soma to distal dendrites [139], and co-clustering of
a subpopulation of Cav2.1 with the calcium-activated
potassium channels BK and SK2 in the PC somata and
primary dendrites [139].
Cav2.1 co-localises with mGluR1 mainly in the molecular
layer of the cerebellum (except for the interneuron somata),
whereas only weak staining was seen in the PC layer [131].
Q-type VGCCs are found in cerebellar granule neu-
rons and the hippocampus.
Antigen-specific assays
All studies published so far used 125I-ω-conotoxin-based
RIAs employing native VGCC from human or non-specified homogenised cerebellum tissue extract. There
are some potential limitations. First, 125I-ω-conotoxin
MVIIC may not be completely specific for CaV2.1
(α1A, P/Q-type) channels; it has also been reported to
block Cav2.2 (α1B, N-type), albeit with lower affinity.
Similarly, 125I-ω-conotoxin GVIA might possibly label
also P2X receptors. Second, subclinical LEMS had not
been excluded by electrophysiological studies in all pa-
tients, and some indeed later developed clinical or
electromyographic features of LEMS. Establishing re-
combinant assays for VGCC has turned out to be chal-
lenging; so far, no CBA or Western blot has been
reported. Also, no RIA that would differentiate be-
tween P- and Q-type VGCC antibodies exists to date.
Assays using omega-agatoxin IVA, a P-type specific
blocker, are currently under development.
CSF testing
In the study by Graus et al., 7/15 CSF samples had anti-
P/Q-type VGCC, with evidence of intrathecal synthesis
as determined by calculation of the anti-VGCC-specific
antibody index in four [109]. Intrathecal synthesis was
also suggested by very high CSF anti-VGCC concentra-
tion compared to serum in another study [112].
Association with other autoantibodies
In SCLC patients with PCD, anti-VGCC have been re-
ported in association with anti-Hu [109, 113–115], anti-
Yo [113, 140], anti-Zic4 [141] and, with particularly high
frequency, SOX1 antibodies [141]. Bürk et al. found no
association of anti-P/Q VGCC with Hu, Ri, Yo or
amphiphysin in 67 patients with idiopathic cerebellar de-
generation [110].
While two studies detected antibodies against
VGCC subunit other than alpha-1 in a subset of pa-
tients with LEMS [142–144], no reactivity to the β4
or γ2 auxiliary subunits of VGCC was found in sera
from PCD patients in a HEK293 CBA [141]. How-
ever, the authors of the latter study identified in a
single patient with SCLC-associated PCD and anti-P/
Q-type VGCC a novel autoantibody to the cytoskel-
etal matrix of the nerve terminals active zone (CAZ)
protein ELKS1 (also termed ERC1) [141], which was
recently shown to interact and co-localise with the
auxiliary β4 subunit of VGCC [145]. In parallel, the
same antigen was identified by another group in pa-
tients with LEMS [146].
Pathogenetic relevance
Anti-VGCC autoantibodies are known to be patho-
genic in LEMS [147]. However, there is also strong evi-
dence for a pathogenic role of anti-P/Q-type VGCC in
PCD, in line with the fact that P/Q-type VGCCs are
present on the cell surface and thus accessible to
Fig. 7 Expression of Cav2.1 in the mouse cerebellum as detected by IHC (modified image from Mallmann RT et al. Ablation of Ca(V)2.1 voltage-gated
Ca2+ channels in mouse forebrain generates multiple cognitive impairments. PLoS One 2013 Oct 31;8(10):e78598 doi: 10.1371/journal.pone.0078598. ©
2013 Mallmann et al.). Note that IHC is not an established method for the detection of anti-VGCC autoantibodies, which are usually determined by RIA
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indeed demonstrated using cerebellar slice culture and PC
culture models [117, 148]. Most importantly, Martín-Gar-
cía et al. reported that intrathecal injection of IgG purified
from the serum of a P/Q-type VGCC antibody-positive
patient with PCD and LEMS (but not IgG from controls)
induced marked, reversible ataxia in mice [30]. As no
human complement was co-injected and symptoms were
reversible, it is most likely that the effect was caused by
functional blocking of VGCCs.
In an earlier study, Liao et al. had demonstrated that
injection of a polyclonal peptide antibody against a major
immunogenic region in P/Q-type VGCCs (the extracellu-
lar domain-III S5–S6 loop) was capable of inhibiting
VGCC function in neuronal and recombinant VGCCs,
altering cerebellar synaptic transmission by attenuating
Ca2+ currents and causing cerebellar ataxia in mice [149].
Fukuda et al. found a reduction in the quantity of
cerebellar P/Q-type VGCC in human autopsy cerebellar
tissues from three PCD/LEMS patients compared withtissues from six disease controls, including one with
LEMS but no PCD; the decrease was most pronounced in
the molecular layer [150]. In line with a contribution of
anti-VGCC to this finding, the ratio of autoantibody-
VGCC complexes to total P/Q-type VGCCs in PCD/LEMS
tissue was increased in these patients, as demonstrated by
autoradiography using 125I-ω-conotoxin MVIIC.
The absence of PCD in many anti-VGCC-positive pa-
tients with LEMS and the absence of LEMS in some
PCD patients with high antibody titres are not well
understood. Of note, intrathecal injection of IgG from a
patient with anti-P/Q-type VGCC and LEMS but not
PCD did not induce ataxia in mice in the above-cited
study by Martín-García et al. [30]. Together, this could
indicate that differences in anti-VGCC fine specificity
play a role. However, alternative explanations such as
site-specific compensatory upregulation of other VGCC
subtypes cannot be ruled out [109].
The VGCC subtype specificity was investigated by
Pinto et al., who demonstrated that IgG antibodies to
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LEMS patients caused a significant dose-dependent re-
duction in the K+-stimulated Ca2+ increase in HEK293
cells expressing the alpha1A subunit of P/Q-type VGCC
but not in cells expressing the N-type VGCC-defining
alpha1B subunit (Cav2.2), the L-type VGCC-related
alpha1D or alpha1C subunits (Cav1.2 and Cav1.3, respect-
ively), or the R-type-defining alpha1E subunit (Cav2.3)
[148]. In line with this finding, incubation of cultured rat
cerebellar neurons with LEMS IgG was followed by a
reduction in P-type current in Purkinje cells and in both
P- and Q-type currents in granule cells [148].
A pathogenic role of the antibody is further sup-
ported by the finding of CSF positivity and even
intrathecal anti-VGCC synthesis in patients with
VGCC-PCD [109] and by molecular findings indicating
that malfunction of VGCC causes hereditary ataxia
(though polyglutamine-mediated cell toxicity plays a
major role as well in some of the latter cases). Whether
other factors in addition to antibody-mediated mecha-
nisms, such as T-cell-mediated mechanisms, play a role
is as yet unknown.
Molecular genetics
Different mutations of the CACNA1A genes, which
encode the immunogenic alpha-1A VGCC subunit
(Cav2.1), can produce the autosomal dominant SCA type
6, episodic ataxia type 2 (EA2) or familial hemiplegic mi-
graine 1 (FHM1). SCA6 is characterised by initially mild
but slowly progressive gait and limb ataxia with dysarth-
ria, decreased muscle tonus, horizontal and vertical gaze
nystagmus (often presymptomatic), abnormal vestibulo-
ocular reflex, cerebellar atrophy affecting the vermis
more than the hemispheres with extensive loss of PCs
and proliferation of Bergmann glia [151–156]; addition-
ally, in rare patients, neuropathy [157, 158] is caused by
an expanded CAG(n) repeat in the C-terminal coding
region of CACN1A [152, 154].
Two mutations causing a disrupted reading frame
[159], two splice mutations in the CACNA1A gene
[160], several (partly large-scale and partly exonic) dele-
tions [161, 162] and a duplication in CACNA1A [162]
have been identified as causes of EA2. EA2 is an auto-
somal dominant disorder with onset in childhood or
early adolescence that is characterised by paroxysmal
attacks of ataxia, vertigo and nausea responsive to
acetazolamide. Episodes can last from minutes to days
and can be associated with, among other symptoms,
hemiplegia and headache, including migraine. Cerebel-
lar atrophy affecting predominantly the vermis [163]
and persistent, attack-independent symptoms of ataxia
may develop.
Finally, cerebellar atrophy and persisting ataxia occur
also in FHM1, an autosomal dominant disorder causingmigraine with hemiplegic (and at least one other) aura
symptoms. FHM1 is caused by missense mutations in
the P/Q-type VGCC gene in 50 % of affected families,
including all of those with permanent cerebellar symp-
toms [159, 164, 165].
Similarly, in mice several spontaneous or induced
mutations have been described that further underline
the high importance of VGCC for proper cerebellar
function [166–169]. Mice lacking P/Q-type VGCC are
ataxic and dystonic, have absence seizures and die
within 3 weeks [166]. A missense mutation in the
alpha1A VGCC subunit affecting the pore lining region
and leading to a reduction in channel function was
shown to underlie ataxia (and seizures) in the ‘totter-
ing’ mouse [169, 170]. In the homozygous ‘leaner’
mouse, a substitution in the VGCC alpha1A gene
causing splicing failures results in reduced P-type
calcium currents predominantly in PCs and severe
ataxia accompanied by significant loss in PC numbers
[169, 171, 172].
Note to the reader
In the following third part of this series, we will review
the current knowledge on anti-Tr/DNER-, anti-Nb/
AP3B2-, anti-Yo/CDR2- and PCA-2-associated ACA,
discuss diagnostic pitfalls and give a summary and out-
look [173].
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type 2; EGF: epidermal growth factor; ELISA: enzyme-linked immunosorbent
assay; ER: endoplasmic reticulum; FHM1: familial hemiplegic migraine 1;
FITC: fluorescein isothiocyanate; GABA: γ-aminobutyric acid; GABABR: GABA
type B receptor; GAD: glutamic acid decarboxylase; GAP: Rho GTPase-
activating protein; GFAP: glial fibrillary acidic protein; GL: granular layer;
GluR: ionotropic glutamate receptors; GluRδ2: glutamate receptor delta-2;
GRAF1: GTPase regulator associated with focal adhesion kinase 1;
HEK: human embryonic kidney; IB: immunoblot assay;
ICC: immunocytochemistry; IIF: indirect immunofluorescence;
IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M;
IHC: immunohistochemistry; IP: immunoprecipitation assay; IP3: inositol
1,4,5-trisphosphate; IRBIT: IP3 receptor-binding protein released with IP3;
ITPR1: inositol 1,4,5-trisphosphate receptor, type 1; IVIG: intravenous
immunoglobulins; IVMP: intravenous methylprednisolone; kDa: kilodalton;
LEMS: Lambert–Eaton myasthenic syndrome; LGI1: leucine-rich, glioma
inactivated 1; LTD: long-term depression; LTP: long-term potentiation;
mGluR1: metabotropic glutamate receptor 1; ML: molecular layer;
MRI: magnetic resonance imaging; mRNA: messenger RNA; NMDA:
N-methyl-D-aspartate; NMO: neuromyelitis optica; NSCLC: non-small
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PC: Purkinje cell; PCA: Purkinje cell antibody; PCD: paraneoplastic
cerebellar degeneration; PCL: PC layer; PF: parallel fibres;
PIP2: phosphatidyl 4,5-bisphosphate; PKCγ: protein kinase C gamma;
PLCβ3: phospholipase Cβ3; PSD: postsynaptic density; RACK: receptors
for activated C kinases; RhoA: Ras homolog gene family, member A;
RIA: radioimmunoprecipitation assay; RNA: ribonucleic acid;
SCA: spinocerebellar ataxia; SCLC: small-cell lung cancer; SOX:
sex-determining region Y-box; TRPC: canonical transient receptor
potential channel; TUNEL: TdT-mediated dUTP-biotin nick end labelling;
VGCC: voltage-gated potassium channel; VGKC: voltage-gated potassium
channel; WB: Western blot; WM: white matter.
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